Regulatory press releases

Kallelse till årsstämma i Nanologica AB (publ)

28 April, 2021

Aktieägarna i Nanologica AB (publ), org.nr 556664-5023 (”Bolaget”) kallas härmed till årsstämma torsdagen den 27 maj 2021. Mot bakgrund av risken för spridning av Covid-19 och myndigheternas föreskrifter/råd om undvikande av sammankomster har styrelsen beslutat att bolagsstämman ska genomföras utan fysisk närvaro genom att aktieägare utövar sin rösträtt endast genom poströstning. Någon fysisk sammankomst kommer således inte att hållas. Rätt att delta vid stämman Aktieägare som önskar delta i årsstämman ska: dels vara registrerad i

Nanologica Interim Report Jan-Mar 2021

23 April, 2021

SUMMARY OF THE PERIOD FINANCIAL OVERVIEW Net revenue increased by 54 percent to TSEK 5,622 (3,654) The operating profit and loss for the period was TSEK -6,768 (-6,032) Profit and loss after tax for the period was TSEK -7,845 (-6,705) Earnings per share for the period was SEK -0.28 (-0.40) Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST QUARTER Test material from

Nanologica Announces Date Change for Annual Report

21 April, 2021

Nanologica AB (publ) has changed the previously disclosed publication date of April 23, 2021 for the company’s annual report 2020 to May 5, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual Report 2020 May 5, 2021 Interim report January-June 2021

Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB

13 April, 2021

Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27. Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of Technology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021. Before that, Thomas was the Vice President

Nanologica Announces Date Change for Interim Reports for First and Second Quarter

30 March, 2021

Nanologica AB (publ) has changed the previously disclosed publication date of May 7, 2021 for the Company’s interim report for the first quarter 2021 to April 23, 2021. In addition, the date for the interim report for the second quarter 2021 has been changed from August 27, 2021 to July 9, 2021. Financial calendar 2021 Interim report January-March 2021 April 23, 2021 Annual Report 2020

Change in Number of Shares in Nanologica AB

26 February, 2021

The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised. A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.